Relapsed or refractory multiple myeloma: the decisions you may face
4 treatment settings, 3 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.
First relapse, lenalidomide-refractory
Daratumumab or isatuximab with carfilzomib or pomalidomide and dexamethasone; belantamab mafodotin with bortezomib- or pomalidomide-dexamethasone (DREAMM-7, DREAMM-8); cilta-cel after one to three lines (CARTITUDE-4).
The CD38 antibody that turned triplets into quadruplets: adding it to standard induction roughly halves the risk of myeloma progressing.
Isatuximab is Sanofi's CD38 antibody, approved in frontline transplant-ineligible myeloma (IMROZ) and, from July 2026, as an under-the-skin injection.
Carfilzomib is a second-generation proteasome inhibitor with less nerve damage but more heart and blood-pressure effects.
The third-generation thalidomide analogue for myeloma that has failed lenalidomide, and since 2020 the first new drug for Kaposi sarcoma in two decades.
Dexamethasone is a long-acting glucocorticoid steroid that kills lymphoid cancer cells directly, which is why it sits in nearly every myeloma regimen and in childhood leukaemia and lymphoma protocols. It is also the standard drug for preventing chemotherapy sickness and for brain swelling and spinal cord compression; high blood sugar, insomnia, muscle wasting and infection follow prolonged use.
A myeloma ADC that was withdrawn in 2022 then came back in 2025 after strong trials in earlier lines.
Ciltacabtagene autoleucel is a one-time BCMA CAR-T for myeloma that, in CARTITUDE-4, cut the risk of death by about 45% compared with standard regimens.
- Tests Belantamab mafodotinRelapsed myeloma after ≥1 line: belantamab-Vd vs Dara-Vd
PFS 36.6 vs 13.4 months, HR 0.41; OS HR 0.58.
Progression-free survival (median) (months): Belantamab-Vd 36.6 (n=243) vs Dara-Vd 13.4 (n=251) · HR 0.41 · source - Tests Belantamab mafodotinRelapsed myeloma after ≥1 line including lenalidomide: belantamab-Pd vs Pom-Vd
PFS HR 0.52.
Progression-free survival at 12 months (%): Belantamab-Pd 71 (n=155) vs Pom-Vd 51 (n=147) · HR 0.52 · source - Lenalidomide-refractory myeloma after 1-3 prior lines: cilta-cel vs Pom-Vd or Dara-Pd
PFS HR 0.26; OS HR 0.55.
- Smoking induces CYP1A2 and lowers exposure by about a third.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Neutropenia (grade 3+) · CARTITUDE-4, n=188 | - | 95% |
| Infections (grade 3+) · CARTITUDE-4, n=188 | - | 24% |
| Hypogammaglobulinaemia · CARTITUDE-4, n=188 | 94% | 9% |
| Cytokine release syndrome · CARTITUDE-4, n=188 | 78% | 3% |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
- Between Daratumumab, Isatuximab, Carfilzomib and the other options, which do you recommend for me, and what about my case would make you choose differently?Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- How closely do I match the people in DREAMM-7 and DREAMM-8, and does that change what the results mean for me?Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
- Which side effects of Ciltacabtagene autoleucel are most likely for me, which are reversible, and which would make us stop?Why: The recorded rates below come from labels and trials; your own risk depends on dose, other medicines and your health.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- Does your recommendation follow the current guideline (NCCN Guidelines: Multiple Myeloma), and if it departs from it, why?Why: Departures from guidelines are sometimes right for an individual; they should be explained.
- For my situation (first relapse, lenalidomide-refractory), which of the standard options do you recommend and why?Why: Guideline options include: Daratumumab or isatuximab with carfilzomib or pomalidomide and dexamethasone; belantamab mafodotin with bortezomib- or pomalidomide-dexamethasone (DREAMM-7, DREAMM-8); cilta-cel after one to three lines (CARTITUDE-4).
- Am I a candidate for Daratumumab, Isatuximab, Carfilzomib or related drugs, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of DREAMM-7 and DREAMM-8 apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Add these to your appointment list, or take the full question set for this cancer.
Triple-class exposed, two or more prior lines
BCMA CAR-T (cilta-cel or ide-cel, KarMMa-3) where slots and fitness allow; BCMA bispecific (teclistamab, elranatamab, linvoseltamab) otherwise; teclistamab-daratumumab (MajesTEC-3).
Ciltacabtagene autoleucel is a one-time BCMA CAR-T for myeloma that, in CARTITUDE-4, cut the risk of death by about 45% compared with standard regimens.
Idecabtagene vicleucel was the first myeloma CAR-T (2021) and is now approved after two prior lines based on KarMMa-3.
Teclistamab was the first off-the-shelf bispecific for multiple myeloma, and is now approved after just one prior line of therapy.
Elranatamab is Pfizer's BCMA bispecific, given under the skin every week then every two weeks, for myeloma after four prior lines.
Linvoseltamab is Regeneron's BCMA bispecific, approved in July 2025 with the highest complete-response rate of the class in its pivotal study.
- Tests Idecabtagene vicleucelTriple-class-exposed myeloma after 2-4 prior lines: ide-cel vs standard regimens
PFS 13.3 vs 4.4 months, HR 0.49.
Progression-free survival (median) (months): Ide-cel 13.3 (n=254) vs Standard regimens 4.4 (n=132) · HR 0.49 · source - Relapsed/refractory myeloma after ≥3 lines, triple-class exposed: cilta-cel single infusion
ORR 98%; ~33% progression-free at 5 years without maintenance.
- Tests TeclistamabRelapsed/refractory myeloma after ≥3 lines: teclistamab monotherapy
ORR 63%, ≥CR 39%.
- Tests TeclistamabRelapsed/refractory myeloma after 1-3 prior lines: teclistamab + daratumumab vs Dara-Pd or Dara-Vd
36-month PFS 83.4% vs 29.7%; HR ~0.17.
Progression-free survival at 36 months (%): Teclistamab + daratumumab 83.4 vs Dara-Pd / Dara-Vd 29.7 · HR 0.17 · source - Tests LinvoseltamabRelapsed/refractory myeloma after ≥3 lines: linvoseltamab 200 mg
ORR 70%, ≥CR 45%.
- Tests ElranatamabRelapsed/refractory myeloma after ≥3 lines, BCMA-naive: elranatamab monotherapy
ORR 61%.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Neutropenia (grade 3+) · CARTITUDE-4, n=188 | - | 95% |
| Infections (grade 3+) · CARTITUDE-4, n=188 | - | 24% |
| Hypogammaglobulinaemia · CARTITUDE-4, n=188 | 94% | 9% |
| Cytokine release syndrome · CARTITUDE-4, n=188 | 78% | 3% |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Neutrophils decreased · MajesTEC-1 | 88% | 70% |
| Pneumonia · MajesTEC-1 | 24% | 15% |
| Neurologic toxicity · ICANS 6% | 60% | 6% |
| Musculoskeletal pain · MajesTEC-1 | 44% | 4.2% |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
- Between Ciltacabtagene autoleucel, Idecabtagene vicleucel, Teclistamab and the other options, which do you recommend for me, and what about my case would make you choose differently?Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- How closely do I match the people in KarMMa-3 and CARTITUDE-1, and does that change what the results mean for me?Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
- Which side effects of Ciltacabtagene autoleucel or Teclistamab are most likely for me, which are reversible, and which would make us stop?Why: The recorded rates below come from labels and trials; your own risk depends on dose, other medicines and your health.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- Does your recommendation follow the current guideline (NCCN Guidelines: Multiple Myeloma), and if it departs from it, why?Why: Departures from guidelines are sometimes right for an individual; they should be explained.
- For my situation (triple-class exposed, two or more prior lines), which of the standard options do you recommend and why?Why: Guideline options include: BCMA CAR-T (cilta-cel or ide-cel, KarMMa-3) where slots and fitness allow; BCMA bispecific (teclistamab, elranatamab, linvoseltamab) otherwise; teclistamab-daratumumab (MajesTEC-3).
- Am I a candidate for Ciltacabtagene autoleucel, Idecabtagene vicleucel, Teclistamab or related drugs, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of KarMMa-3 and CARTITUDE-1 apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Add these to your appointment list, or take the full question set for this cancer.
After BCMA-directed therapy
Talquetamab against GPRC5D (MonumenTAL-1); selinexor combinations; CELMoDs and trispecifics in trials.
Talquetamab is the first drug against GPRC5D, a second myeloma target used after BCMA therapies stop working; taste and skin side effects are its signature.
Selinexor is a first-in-class pill that traps tumour-suppressor proteins inside the nucleus; approved in myeloma, it failed its endometrial cancer test in 2026.
Iberdomide is a far more potent successor to lenalidomide, now in phase 3 as post-transplant maintenance and in relapsed disease.
Mezigdomide is the most potent oral cereblon modulator, producing responses in about 40% of triple-class-refractory myeloma with dexamethasone alone.
- Tests TalquetamabRelapsed/refractory myeloma after ≥3 lines: talquetamab (weekly or biweekly)
ORR ~73%.
Objective response rate (%): Talquetamab 0.8 mg/kg Q2W 71.7 (n=145) vs Talquetamab 0.4 mg/kg QW 74.1 (n=143) · source
- Nausea and anorexia are near-universal: prophylactic 5-HT3 antagonist plus olanzapine or dexamethasone.
- Between Talquetamab, Selinexor, Iberdomide and the other options, which do you recommend for me, and what about my case would make you choose differently?Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- How closely do I match the people in MonumenTAL-1, and does that change what the results mean for me?Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- Does your recommendation follow the current guideline (NCCN Guidelines: Multiple Myeloma), and if it departs from it, why?Why: Departures from guidelines are sometimes right for an individual; they should be explained.
- For my situation (after bcma-directed therapy), which of the standard options do you recommend and why?Why: Guideline options include: Talquetamab against GPRC5D (MonumenTAL-1); selinexor combinations; CELMoDs and trispecifics in trials.
- Am I a candidate for Talquetamab, Selinexor, Iberdomide or related drugs, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of MonumenTAL-1 apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Add these to your appointment list, or take the full question set for this cancer.
Toxicity management
Step-up dosing and tocilizumab for cytokine release syndrome, immunoglobulin replacement and antimicrobial prophylaxis on bispecifics, neurological monitoring after cilta-cel, ocular examinations on belantamab.
This setting names no product or technology record yet; the approach above is the standard as written. Ask your team which specific treatments they mean.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
No side-effect rates or interaction flags are recorded for these options yet. The side-effect lookup and interaction checker cover the products that have them.
- Which specific treatments are you proposing for this setting, and what are the alternatives?Why: The standard of care here is described in words rather than named products; ask for the names.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- For my situation (toxicity management), which of the standard options do you recommend and why?Why: Guideline options include: Step-up dosing and tocilizumab for cytokine release syndrome, immunoglobulin replacement and antimicrobial prophylaxis on bispecifics, neurological monitoring after cilta-cel, ocular examinations on belantamab.
Add these to your appointment list, or take the full question set for this cancer.